BPC-157 2026 research review — Yildirim ex-vivo human mammary artery vasorelaxation, the 2010-2023 mechanism foundation (Cerovecki, Chang FAK-paxillin, Sikiric), and honest counter-evidence.
Field-by-field guide to interpreting a research peptide Certificate of Analysis — HPLC purity, MS identity, Karl Fischer, endotoxin, batch traceability, and red flags.
10-point framework for evaluating a vendor of research peptides — third-party HPLC, COA standards, regulatory compliance posture, sourcing transparency, and red flags.
What published research actually says about BPC-157 and TB-500 — sequences, study models, human-evidence gaps, and why no combination study exists.
Plain-language explanation of FDA regulations for research peptides, ‘for research only’ labeling rules, 2025–2026 enforcement actions, and state-level variation.
SLU-PP-332 ERRα agonist deep dive — mechanism, the 2023 Saint Louis University publication, exercise-mimetic transcriptional signature, and 2024-2026 follow-up research.
Pillar guide to longevity research peptides — MOTS-C, SLU-PP-332, GHK-Cu, 5-Amino-1MQ — mechanisms, 2024–2026 data, and comparative pharmacology.
TRIUMPH-4 retatrutide Phase 3 trial design — Phase 3 outcomes pending; Phase 2 data (PMID 37366315) shows up to 24.2% mean weight reduction at 48 weeks (12 mg).
Pillar guide to GH-axis research peptides — CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MOTS-C — covering 2024–2026 trial data and comparative pharmacology.
Side-by-side comparison of CJC-1295 (DAC-modified GHRH) and Sermorelin (native GHRH 1-29) — pharmacokinetics, pulsatility, receptor complementarity, and research applications.